small molecule

TRUSELTIQ

INFIGRATINIB PHOSPHATE

Loss of exclusivityDecember 2034latest FDA-listed patent expiry

CompanyHELSINN HEALTHCARE SA

Drug detail

Brand name	TRUSELTIQ
Active ingredient	INFIGRATINIB PHOSPHATE
Strength	25MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	May 2021
Marketing status	DISCN

Listed patents

Patent	Expires	Type
10278969	December 2034	product
11160804	December 2034	product
8552002	August 2029	substance, product
9067896	August 2028	substance

Regulatory exclusivity

Code	Expires
ODE-353	May 2028
NCE	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from HELSINN HEALTHCARE SA